NEWS UPDATE As of early January 2021, the covid-19 vaccine mRNA-1273 Sars-CoV-2, from the pharmaceutical company Moderna, is expected to be approved for use in the European Union. In France, this vaccine is to be offered first to elderly residents of nursing homes and similar facilities, and to certain health professionals. What are the main evaluation data obtained with this vaccine in these populations?